SVRA
Savara Inc. [SVRA] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
SVRA Stock Summary
Top 10 Correlated ETFs
SVRA
Top 10 Correlated Stocks
SVRA
In the News
SVRA Financial details
Company Rating
-
Market Cap
700.41M
Income
-52.38M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
37
Optionable
No
Shortable
Yes
Earnings
13 May 2024
P/E
-14.85
Forward P/E
-
PEG
-5.44
P/S
-
P/B
4.8
P/C
-
P/FCF
-13.05
Quick Ratio
18.88
Current Ratio
18.98
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.32
EPS next Y
-
EPS next Q
-
EPS this Y
32%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-10.5%
-
-
-
-
SMA20
-
SMA50
33.33%
SMA100
100%
Inst Own
-
Inst Trans
-
ROA
-26%
ROE
-43%
ROC
-0.31%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.69-5.7
52W High
-13.7%
52W Low
+331.5%
RSI
73
Rel Volume
0.94
Avg Volume
791.03K
Volume
739.62K
Perf Week
2.01%
Perf Month
19.86%
Perf Quarter
50.87%
Perf Half Y
35.27%
-
-
-
-
Beta
0.697
-
-
Volatility
0.12%, 0.37%
Prev Close
-2.15%
Price
4.315
Change
-0.58%
Company Profile
- Volume Average 791.03K
- Market Capitalization 700.41M
- Employee 37
- CEO Mr. Matthew Pauls J.D., M.B.A.
- Headquarters Austin,TX,US
- IPO Date 2017-04-28
-
Website
https://www.savarapharma.com 
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
